Form 8-K - Current report:
SEC Accession No. 0001558370-25-004070
Filing Date
2025-03-31
Accepted
2025-03-31 07:05:13
Documents
16
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pmn-20250331x8k.htm   iXBRL 8-K 37676
2 EX-99.1 pmn-20250331xex99d1.htm EX-99.1 131744
3 GRAPHIC pmn-20250331xex99d1001.jpg GRAPHIC 6463
  Complete submission text file 0001558370-25-004070.txt   325883

Data Files

Seq Description Document Type Size
4 EX-101.SCH pmn-20250331.xsd EX-101.SCH 4049
5 EX-101.DEF pmn-20250331_def.xml EX-101.DEF 2873
6 EX-101.LAB pmn-20250331_lab.xml EX-101.LAB 17908
7 EX-101.PRE pmn-20250331_pre.xml EX-101.PRE 11839
18 EXTRACTED XBRL INSTANCE DOCUMENT pmn-20250331x8k_htm.xml XML 5044
Mailing Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2
Business Address SUITE 200, 1920 YONGE STREET TORONTO A6 M4S 3E2 416-847-6898
ProMIS Neurosciences Inc. (Filer) CIK: 0001374339 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41429 | Film No.: 25788815
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)